Rheumatology is a long game. You watch a rheumatoid arthritis patient across years of DMARD changes, read a lupus flare against a dozen prior visits, and reason about a gout patient’s urate over time. Half the visit is a running list of medications with monitoring attached to each. An ambient AI medical scribe drafts your RA, lupus, gout, and psoriatic arthritis notes from what you say during the visit, then hands the draft back about two minutes after the patient leaves. Here is the catch up front: the scribe has no memory of the last visit, so any trend you want in the note is a trend you speak. You review the draft, confirm the coding, and sign.
Key takeaways
- The scribe drafts rheumatology notes plus ICD-10 suggestions about two minutes after the visit; you review and sign.
- It has no memory of prior visits, so DAS28 history, DMARD escalation, and disease-activity trends must be spoken during the visit.
- It captures joint counts and disease-activity scores from your dictation. It does not examine the patient or calculate a score.
- The prescription draft reflects the dose you dictated; monitoring and toxicity checks stay your call, since the scribe does not screen labs.
- Audio is discarded the moment the note drafts. Nothing is recorded.
From end of visit to drafted note
Assist tier, per clinician, annual billing
Prior-visit data the scribe stores or recalls
Source: Patient Square product specifications, 2026.
How an ambient scribe fits a rheumatology visit
A rheumatology follow-up has a shape. You ask how the joints have been, run a joint count, gauge disease activity, and review the medication list against what the labs are doing. You decide whether the current DMARD is holding, whether to escalate, whether a biologic is next, whether an infusion is due. Then you set the monitoring interval and the follow-up.
The scribe listens through all of it. When you say the DAS28 is 3.2 and the patient has moved from moderate to low disease activity on methotrexate, that goes in the note. When you count five tender and three swollen joints and name them, that lands in the note. When you decide to add a TNF inhibitor because the methotrexate has plateaued, the plan reflects it. Two minutes after the patient leaves, you have a draft.
Because the story is longitudinal, your narration during the visit is what builds the note. The scribe carries nothing forward and infers nothing about where the patient was six months ago.
The no-memory design and the disease-activity trend
This is the part that changes how you dictate in rheumatology. A DAS28 of 3.2 tells you almost nothing on its own. It matters because it was 5.1 before you started treatment, and now the patient is close to remission. The scribe does not know that. It has no memory of the prior visit and no view into your flowsheet.
So the habit is to speak the arc. Say the DAS28 came down from 5.1 to 3.2 over the last four months on methotrexate, and the trend, the drug, and the response are all in the note because you said them. Leave it out and the note holds only the single number you mentioned this visit.
You are probably already saying most of this to the patient. “Your disease activity has dropped from 5.1 to 3.2 since we started the methotrexate, which is real progress, so I want to hold the current dose and recheck in three months.” Say that out loud and the trend, your read on it, and the plan land in the draft. The scribe turns the conversation you are already having into the record.
What a rheumatology scribe must capture
The vocabulary here is specific, and the scribe has to land it when you speak it. The American College of Rheumatology’s treatment-to-target guidance leans on documented disease-activity measures and joint assessment, so getting these into the note is what makes the record defensible.
| Note element | What you say out loud | What the scribe drafts |
|---|---|---|
| Joint count | ”Five tender, three swollen: both wrists, right MCP 2 and 3, left knee” | Tender and swollen counts with joints named |
| Disease-activity score | ”DAS28 down from 5.1 to 3.2, low activity now” | Score and trend as narrated |
| DMARD management | ”Holding methotrexate 20 milligrams weekly, tolerating well” | Current DMARD and dose |
| Biologic escalation | ”Adding adalimumab, methotrexate has plateaued” | Escalation decision in the plan |
| Infusion note | ”Rituximab infusion given, no reaction, premedicated per protocol” | Infusion event as stated |
| Extra-articular findings | ”No rash, no serositis, no new sicca symptoms” | Review of systems as narrated |
| Medication monitoring | ”Ordering CBC and LFTs for methotrexate, due this month” | Monitoring labs in the plan |
| Follow-up interval | ”Recheck DAS28 and labs in three months” | Interval and orders |
The joint count and the disease-activity score carry weight for both management and coding. If you count the joints, name them, and state the score, the note supports the complexity of the visit. If you skip them, the scribe cannot supply them, because it never saw the patient’s hands.
Joint counts and scores, captured not calculated
Worth being blunt about this. The scribe does not examine the patient, it does not count joints, and it does not compute a DAS28 or CDAI. It records what you say. If you state five tender and three swollen joints and call the DAS28 low at 3.2, that goes in the note because you spoke it. If you assess an infusion patient and describe no reaction, the scribe writes down your assessment.
The judgment about disease activity, about whether the current regimen is working, about whether the patient is in remission, that is yours. The scribe documents your assessment. It does not produce it, and it does not know a CDAI from a coffee order unless you say the number.
The prescription draft, and where monitoring stays
Rheumatology needs a hard line here, because so much of the specialty is high-stakes drug management. When your plan includes a medication change, the scribe drafts a prescription from what you said. If you start adalimumab or continue methotrexate at 20 milligrams weekly, the draft reflects that because you dictated it. It writes the order out so you are not retyping it.
What the scribe does not do is screen labs, check the dose, or flag toxicity. There is no logic that reads a rising transaminase and warns you off the methotrexate, no alert for a low white count before a biologic. DMARD and biologic monitoring, the CBC and LFTs, the TB screen before a TNF inhibitor, the decision to hold a dose, all of that is exactly the clinical judgment you make on every one of these patients, and it stays entirely with you. You read the draft, confirm the dose and the monitoring against the labs you are looking at, and sign.
The draft never goes to a pharmacy. There is no e-prescribing connection and nothing transmits. You act on it in your own workflow. Our post on prescription draft safety covers how the draft works and why the clinician stays the safety check.
ICD-10 suggestions for the rheumatology visit
After the visit the scribe offers ICD-10 suggestions from what you said. Common ones in this specialty:
| Condition | ICD-10 suggestion |
|---|---|
| Rheumatoid arthritis with rheumatoid factor | M05.- family |
| Systemic lupus erythematosus | M32.- family |
| Gout | M10.- family |
| Psoriatic arthritis | L40.5- family |
These are suggestions to speed your coding, not a final answer. RA coding in ICD-10 wants the site and often the serostatus and organ involvement, so you confirm the specificity. Lupus with organ involvement codes differently from lupus without, and that distinction is yours to resolve. Our explainer on how ICD-10 suggestions are generated has the detail.
Security and ownership
Rheumatology records, with their long medication histories and immunosuppression, are protected health information and are handled accordingly. Audio is processed in memory and discarded the moment the note drafts, so no recording persists. Notes are always in English, they are encrypted in transit with TLS 1.2 or higher and at rest with AES-256, they belong to your practice, and you can export or delete them any time.
We maintain HIPAA compliant safeguards, offer a signed BAA to every customer, and have a SOC 2 Type II audit underway rather than complete. If compliance is a gate for you, start with the security page and our detail on BAAs and consent.
Where rheumatology fit stands or falls
If you run full RA, lupus, and gout clinics and your notes are eating your evenings, the trade is clear. Speak the joint counts, the scores, and the DMARD reasoning you already discuss with the patient, and the note drafts for your review, with any prescription draft reflecting the dose you set. The fit is strongest for high-volume follow-up practice where the narration is already happening out loud.
Where it stands or falls: the scribe helps most if you narrate the trend and the numbers. If your visits are quiet, or you prefer to reason silently and type your own count, the gain is smaller, and an honest look at your own dictation habits will tell you which camp you are in. Before you commit to anyone, read how to evaluate an AI scribe and our comparison of AI medical scribes. If you co-manage inflammatory patients with primary care, the primary care scribe overview covers that side.
Pricing starts from $79 per clinician per month on the annual Assist plan, with unlimited visits and notes and a 7-day free trial to run it on a real clinic day. It steps up to Copilot at $119 and Autopilot at $199 as you add a bundled AI EHR, messaging, and receptionist and follow-up automation. On Assist the scribe works alongside your existing rheumatology EHR with no integration and no IT project.
Want to see it draft a real RA follow-up?